Recurrent focal segmental glomerulosclerosis after kidney transplantation

Pediatric Nephrology

Volumn 30, Issue 10, 2015, Pages 1793-1802

  Trachtman, Rebecca ^a   Sran, Simranjeet S ^a   Trachtman, Howard ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Circulating factors; Focal segmental glomerulosclerosis; Genetics; Kidney transplant; Plasmapheresis; Recurrent disease; Rituximab

Indexed keywords

ABATACEPT; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCINEURIN INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PODOCIN; RITUXIMAB;

AGE; ARTICLE; FOCAL GLOMERULOSCLEROSIS; HEREDITY; HUMAN; KIDNEY TRANSPLANTATION; MEDICAL CARE; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; RACE DIFFERENCE; RECURRENT DISEASE; SEX DIFFERENCE; ADVERSE EFFECTS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; INCIDENCE; KIDNEY FAILURE, CHRONIC; PROCEDURES; RISK FACTOR;

GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PLASMAPHERESIS; RECURRENCE; RISK FACTORS;

EID: 84940451172     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-015-3062-1     Document Type: Article

References (86)

1. Kiffel J, Rahimzada Y, Trachtman H (2011) Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients. Adv Chronic Kidney Dis 18(5):332–338
2. Cravedi P, Kopp JB, Remuzzi G (2013) Recent progress in the pathophysiology and treatment of FSGS recurrence. Am J Transplant 13(2):266–274
3. Kowalewska J (2013) Pathology of recurrent diseases in kidney allografts: membranous nephropathy and focal segmental glomerulosclerosis. Curr Opin Organ Transplant 18(3):313–318
4. Fatima H, Moeller MJ, Smeets B, Yang HC, D’Agati VD, Alpers CE, Fogo AB (2012) Parietal epithelial cell activation marker in early recurrence of FSGS in the transplant. Clin J Am Soc Nephrol 7(11):1852–1858
5. Hickson LJ, Gera M, Amer H, Iqbal CW, Moore TB, Milliner DS, Cosio FG, Larson TS, Stegall MD, Ishitani MB, Gloor JM, Griffin MD (2009) Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 87(8):1232–1239
6. Mahesh S, Del Rio M, Feuerstein D, Greenstein S, Schechner R, Tellis V, Kaskel F (2008) Demographics and response to therapeutic plasma exchange in pediatric renal transplantation for focal glomerulosclerosis: a single center experience. Pediatr Transplant 12(6):682–688
7. Huang K, Ferris ME, Andreoni KA, Gipson DS (2004) The differential effect of race among pediatric kidney transplant recipients with focal segmental glomerulosclerosis. Am J Kidney Dis 43(6):1082–1090
8. Hwang JH, Han SS, Huh W, Park SK, Joo DJ, Kim MS, Kim YS, Min SI, Ha J, Kim SJ, Kim S, Kim YS (2012) Outcome of kidney allograft in patients with adulthood-onset focal segmental glomerulosclerosis: comparison with childhood-onset FSGS. Nephrol Dial Transplant 27(6):2559–2565
9. Schachter ME, Monahan M, Radhakrishnan J, Crew J, Pollak M, Ratner L, Valeri AM, Stokes MB, Appel GB (2010) Recurrent focal segmental glomerulosclerosis in the renal allograft: single center experience in the era of modern immunosuppression. Clin Nephrol 74(3):173–181
10. Sener A, Bella AJ, Nguan C, Luke PP, House AA (2009) Focal segmental glomerular sclerosis in renal transplant recipients: predicting early disease recurrence may prolong allograft function. Clin Transplant 23(1):96–100
11. Jungraithmayr TC, Bulla M, Dippell J, Greiner C, Griebel M, Leichter HE, Plank C, Tönshoff B, Weber LT, Zimmerhackl LB, German MMF Study Group (2005) Primary focal segmental glomerulosclerosis–long-term outcome after pediatric renal transplantation. Pediatr Transplant 9(2):226–231
12. Nehus EJ, Goebel JW, Succop PS, Abraham EC (2013) Focal segmental glomerulosclerosis in children: multivariate analysis indicates that donor type does not alter recurrence risk. Transplantation 96(6):550–554
13. Maas RJ, Deegens JK, van den Brand JA, Cornelissen EA, Wetzels JF (2013) A retrospective study of focal segmental glomerulosclerosis: clinical criteria can identify patients at high risk for recurrent disease after first renal transplantation. BMC Nephrol 14:47
14. Sharief S, Mahesh S, Del Rio M, Telis V, Woroniecki RP (2011) Recurrent focal segmental glomerulosclerosis in renal allograft recipients: role of human leukocyte antigen mismatching and other clinical variables. Int J Nephrol 2011:506805. doi:10.4061/2011/506805
15. Ponticelli C (2010) Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation. Nephrol Dial Transplant 25(1):25–31
16. Baum MA, Ho M, Stablein D, Alexander SR, North American Pediatric Renal Transplant Cooperative Study (2002) Outcome of renal transplantation in adolescents with focal segmental glomerulosclerosis. Pediatr Transplant 6(6):488–492
17. Sadowski CE, Lovric S, Ashraf S, Pabst WL, Gee HY, Kohl S, Engelmann S, Vega-Warner V, Fang H, Halbritter J, Somers MJ, Tan W, Shril S, Fessi I, Lifton RP, Bockenhauer D, El-Desoky S, Kari JA, Zenker M, Kemper MJ, Mueller D, Fathy HM, Soliman NA, the SRNS Study Group, Hildebrandt F (2014) A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol. doi:10.1681/ASN.2014050489
18. Giglio S, Provenzano A, Mazzinghi B, Becherucci F, Giunti L, Sansavini G, Ravaglia F, Roperto RM, Farsetti S, Benetti E, Rotondi M, Murer L, Lazzeri E, Lasagni L, Materassi M, Romagnani P (2014) Heterogeneous genetic alterations in sporadic nephrotic syndrome associate with resistance to immunosuppression. J Am Soc Nephrol 26:230–236
19. Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, Dahan K, Gubler MC, Niaudet P, Antignac C (2000) NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 24(4):349–354
20. McCarthy HJ, Bierzynska A, Wherlock M, Ognjanovic M, Kerecuk L, Hegde S, Feather S, Gilbert RD, Krischock L, Jones C, Sinha MD, Webb NJ, Christian M, Williams MM, Marks S, Koziell A, Welsh GI, Saleem MA, RADAR the UK SRNS Study Group (2013) Simultaneous sequencing of 24 genes associated with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 8(4):637–648
21. Jungraithmayr TC, Hofer K, Cochat P, Chernin G, Cortina G, Fargue S, Grimm P, Knueppel T, Kowarsch A, Neuhaus T, Pagel P, Pfeiffer KP, Schäfer F, Schönermarck U, Seeman T, Toenshoff B, Weber S, Winn MP, Zschocke J, Zimmerhackl LB (2011) Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation. J Am Soc Nephrol 22(3):579–585
22. Weber S, Gribouval O, Esquivel EL, Morinière V, Tête MJ, Legendre C, Niaudet P, Antignac C (2004) NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int 66(2):571–579
23. Ruf RG, Lichtenberger A, Karle SM, Haas JP, Anacleto FE, Schultheiss M, Zalewski I, Imm A, Ruf EM, Mucha B, Bagga A, Neuhaus T, Fuchshuber A, Bakkaloglu A, Hildebrandt F, Arbeitsgemeinschaft Für Pädiatrische Nephrologie Study Group (2004) Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 15(3):722–732
24. Bertelli R, Ginevri F, Caridi G, Dagnino M, Sandrini S, Di Duca M, Emma F, Sanna-Cherchi S, Scolari F, Neri TM, Murer L, Massella L, Basile G, Rizzoni G, Perfumo F, Ghiggeri GM (2003) Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin. Am J Kidney Dis 41(6):1314–1321
25. Mohey H, Thibaudin L, Laurent B, Berthoux F (2013) The podocin mutation R229Q and early recurrence (within the first year) of glomerular disease after renal transplantation. Ann Transplant 18:436–442
26. Ding WY, Koziell A, McCarthy HJ, Bierzynska A, Bhagavatula MK, Dudley JA, Inward CD, Coward RJ, Tizard J, Reid C, Antignac C, Boyer O, Saleem MA (2014) Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence. J Am Soc Nephrol 25(6):1342–1348
27. McCarthy ET, Sharma M, Savin VJ (2010) Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5(11):2115–2121
28. Chang JW, Pardo V, Sageshima J, Chen L, Tsai HL, Reiser J, Wei C, Ciancio G, Burke GW 3rd, Fornoni A (2012) Podocyte foot process effacement in post-reperfusion allograft biopsies correlates with early recurrence of proteinuria in focal segmental glomerulosclerosis. Transplantation 93(12):1238–1244
29. Shalhoub RJ (1974) Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 2(7880):556–560
30. Savin VJ, McCarthy ET, Sharma M (2003) Permeability factors in focal segmental glomerulosclerosis. Semin Nephrol 23(2):147–160
31. Sharma M, Sharma R, McCarthy ET, Savin VJ (2004) The focal segmental glomerulosclerosis permeability factor: biochemical characteristics and biological effects. Exp Biol Med (Maywood) 229(1):85–98
32. Savin VJ, McCarthy ET, Sharma R, Charba D, Sharma M (2008) Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res 151(6):288–292
33. Schwartz MM (2000) The role of podocyte injury in the pathogenesis of focal segmental glomerulosclerosis. Ren Fail 22(6):663–684
34. Hattori M, Akioka Y, Chikamoto H, Kobayashi N, Tsuchiya K, Shimizu M, Kagami S, Tsukaguchi H (2008) Increase of integrin-linked kinase activity in cultured podocytes upon stimulation with plasma from patients with recurrent FSGS. Am J Transplant 8(7):1550–1556
35. Carraro M, Zennaro C, Artero M, Candiano G, Ghiggeri GM, Musante L, Sirch C, Bruschi M, Faccini L (2004) The effect of proteinase inhibitors on glomerular albumin permeability induced in vitro by serum from patients with idiopathic focal segmental glomerulosclerosis. Nephrol Dial Transplant 19(8):1969–1975
36. Trachtman H, Futterweit S, Singhal PC, Franki N, Sharma M, Sharma R, Savin V (1999) Circulating factor in patients with recurrent focal segmental glomerulosclerosis postrenal transplantation inhibits expression of inducible nitric oxide synthase and nitric oxide production by cultured rat mesangial cells. J Investig Med 47(3):114–120
37. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17(8):952–960
38. Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, McMahan JL, Radeva M, Heil KM, Trautmann A, Anarat A, Emre S, Ghiggeri GM, Ozaltin F, Haffner D, Gipson DS, Kaskel F, Fischer DC, Schaefer F, Reiser J, PodoNet and FSGS CT Study Consortia (2012) Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 23(12):2051–2059
39. Meijers B, Maas RJ, Sprangers B, Claes K, Poesen R, Bammens B, Naesens M, Deegens JK, Dietrich R, Storr M, Wetzels JF, Evenepoel P, Kuypers D (2014) The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int 85(3):636–640
40. Sinha A, Bajpai J, Saini S, Bhatia D, Gupta A, Puraswani M, Dinda AK, Agarwal SK, Sopory S, Pandey RM, Hari P, Bagga A (2014) Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. Kidney Int 85(3):649–658
41. Spinale JM, Mariani LH, Kapoor S, Zhang J, Weyant R, Song PX, Wong HN, Troost JP, Gadegbeku CA, Gipson DS, Kretzler M, Nihalani D, Holzman LB (2014) A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease. Kidney Int. doi:10.1038/ki.2014.346
42. Alachkar N, Wei C, Arend LJ, Jackson AM, Racusen LC, Fornoni A, Burke G, Rabb H, Kakkad K, Reiser J, Estrella MM (2013) Podocyte effacement closely links to suPAR levels at time of post-transplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation 96(7):649–656
43. Franco Palacios CR, Lieske JC, Wadei HM, Rule AD, Fervenza FC, Voskoboev N, Garovic VD, Zand L, Stegall MD, Cosio FG, Amer H (2013) Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation 96(4):394–399
44. Delville M, Sigdel TK, Wei C, Li J, Hsieh SC, Fornoni A, Burke GW, Bruneval P, Naesens M, Jackson A, Alachkar N, Canaud G, Legendre C, Anglicheau D, Reiser J, Sarwal MM (2014) A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med 6(256):256ra136
45. Shishido S, Satou H, Muramatsu M, Hamasaki Y, Ishikura K, Hataya H, Honda M, Asanuma H, Aikawa A (2013) Combination of pulse methylprednisolone infusions with cyclosporine-based immunosuppression is safe and effective to treat recurrent focal segmental glomerulosclerosis after pediatric kidney transplantation. Clin Transplant 27(2):E143–E150
46. Raafat R, Travis LB, Kalia A, Diven S (2000) Role of transplant induction therapy on recurrence rate of focal segmental glomerulosclerosis. Pediatr Nephrol 14:189–194
47. Cheong HI, Han HW, Park HW, Ha IS, Han KS, Lee HS, Kim SJ, Choi Y (2000) Early recurrent nephrotic syndrome after renal transplantation in children with focal segmental glomerulosclerosis. Nephrol Dial Transplant 15:78–81
48. Greenstein SM, Delrio M, Ong E, Feuerstein D, Schechner R, Kim D, Corey H, Kaskel R, Tellis VA, Moritz ML (2000) Plasmapheresis treatment for recurrent focal sclerosis in pediatric renal allografts. Pediatr Nephrol 14:1061–1065
49. Matalon A, Markowitz GS, Joseph RE, Cohen DJ, Saal SD, Kaplan B, D’Agati VD, Appel GB (2001) Plasmapheresis treatment of recurrent FSGS in adult renal transplant recipients. Clin Nephrol 56(4):271–278
50. Ohta T, Kawaguchi H, Hattori M, Komatsu Y, Akioka Y, Nagata M, Shiraga H, Ito K, Takahashi K, Ishikawa N, Tanabe K, Yamaguchi Y, Ota K (2001) Effect of pre- and postoperative plasmapheresis on posttransplant recurrence of focal segmental glomerulosclerosis in children. Transplantation 71(5):628–633
51. Pradhan M, Petro J, Palmer J, Meyers K, Baluarte HJ (2003) Early use of plasmapheresis for recurrent post-transplant FSGS. Pediatr Nephrol 18:934–938
52. Deepens JK, Andresdottir MB, Croockewit S, Wetzels JF (2004) Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplant. Transpl Int 17(3):151–157
53. Otsubo S, Tanabe K, Shinmura H, Ishikawa N, Tokumoto T, Hattori M, Ito K, Nitta K, Akiba T, Nihei H, Toma H (2004) Effect of post-transplant double filtration plasmapheresis on recurrent focal and segmental glomerulosclerosis in renal transplant recipients. Ther Apher Dial 8(4):299–304
54. Hubsch H, Montane B, Abitbol C, Chandar J, Shariatmadar S, Ciancio G, Burke G, Miller J, Strauss J, Zilleruelo G (2005) Recurrent focal glomerulosclerosis in pediatric renal allografts: the Miami experience. Pediatr Nephrol 20:210–216
55. Garcia CD, Bittencourt VB, Tumelero A, Antonello JS, Malheiros D, Garcia VD (2006) Plasmapheresis for recurrent posttransplant focal segmental glomerulosclerosis. Transplant Proc 38(6):1904–1905
56. Pardon A, Audard V, Caillard S, Moulin B, Desvaux D, Bentaarit B, Remy P, Sahali D, Roudot-Thoraval F, Lang P, Grimbert P (2006) Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients. Nephrol Dial Transplant 21(4):1053–1059
57. Fuentes GM, Meseguer CG, Carrion AP, Hijosa MM, Garcia-Pose A, Melgar AA, Torres MN (2010) Long-term outcome of focal segmental glomerulosclerosis after pediatric renal transplantation. Pediatr Nephrol 25(3):529–534
58. Gungor O, Sen S, Kircelli F, Yilmaz M, Sarsik B, Ozkahya M, Hoscoskun C, Ok E, Toz H (2011) Plasmapheresis therapy in renal transplant patients: five-year experience. Transplant Proc 43(3):853–857
59. Gonzalez E, Ettenger R, Rianthavorn P, Tsai E, Malekzadeh M (2011) Preemptive plasmapheresis and recurrence of focal segmental glomerulosclerosis in pediatric renal transplantation. Pediatr Transplant 15(5):495–501
60. Straatmann C, Kallash M, Killackey M, Iorember F, Aviles D, Bamgbola O, Carson T, Florman S, Vehaskari MV (2014) Success with plasmapheresis treatment for recurrent focal segmental glomerulosclerosis in pediatric renal transplant recipients. Pediatr Transplant 18(1):29–34
61. Hattori M, Chikamoto H, Akioka Y, Nakakura H, Ogino D, Matsunaga A, Fukazawa A, Miyakawa S, Khono M, Kawaguchi H, Ito K (2003) A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 42(6):1121–1130
62. Benz K, Dotsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19(7):794–797
63. Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M (2005) Rituximab Treatment for Posttransplant Lymphoproliferative Disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 20(11):1660–1663
64. Pescovitz MD, Book BK, Sidner RA (2006) Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 354(18):1961–1963
65. Hristea D, Hadaya K, Marangon N, Buhler L, Villard J, Morel P, Martin PY (2007) Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 20(1):102–105
66. Kamar N, Faguer S, Esposito L, Guitard J, Nogier MB, Durand D, Rostaing L (2007) Treatment of focal segmental glomerulosclerosis with rituximab: 2 case reports. Clin Nephrol 67(4):250–254
67. Grossmann J, Scheuermann EH, Porubsky S, Kachel HG, Geiger H, Hauser IA (2007) Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis. Transpl Int 20(6):558–562
68. Meyer TN, Thaiss F, Stahl RA (2007) Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis. Transpl Int 20(12):1066–1071
69. El-Firjani A, Hoar S, Karpinski J, Bell R, Deschenes MJ, Knoll GA (2008) Post-transplant focal segmental glomerulosclerosis refractory to plasmapheresis and rituximab therapy. Nephrol Dial Transplant 23(1):425
70. Yabu JM, Ho B, Scandling JD, Vincenti F (2008) Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant 8:222–227
71. Shimizu M, Kitagawa K, Nishio S, Yokoyama T, Furuichi K, Ohta K, Wada T, Yachie A (2010) Successful treatment of recurrent focal segmental glomerulosclerosis after renal transplantation by lymphocytapheresis and rituximab. Transpl Int 9:e53–e55
72. Grenda R, Jarmuzek W, Piatosa B, Rubik J (2011) Long-term effect of rituximab in maintaining remission of recurrent and plasmapheresis-dependent nephrotic syndrome post-renal transplantation—case report. Pediatr Transplant 2(6):e121–e125
73. Sethna C, Benchimol C, Hotchkiss H, Frank R, Infante L, Vento S, Trachtman H (2011) Treatment of recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: effect of rituximab. J Transplant 389542. doi:10.1155/2011/389542
74. Tsagalis G, Psimenou E, Nakopolou L, Laggouranis A (2011) Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation. Artif Organs 35(4):420–425
75. Okamoto M, Koshino K, Sakai K, Nobori S, Matsuyama M, Ushigome H, Okajima H, Masuzawa N, Yoshimura N (2011) A case of recurrent Focal Segmental Glomerulosclerosis (FSGS) involving massive proteinuria (>50 g/day) immediately after renal transplantation. Clin Transplant Suppl 23:53–58
76. Stewart ZA, Shetty R, Nair R, Reed AI, Broohy PD (2011) Case report: successful treatment of recurrent focal segmental glomerulosclerosis with a novel rituximab regimen. Transplant Proc 43(10):3994–3996
77. Audard V, Kamar N, Sahali D, Cardeau-Desangles I, Homs S, Remy P, Aouizerate J, Matignon M, Rostaing L, Lang P, Grimbert P (2012) Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation. Transpl Int 5:e62–e66
78. Kumasi J, Shatat IF, Skversky AL, Woroniecki RP, Del Rio M, Perelstein EM, Johnson VL, Mahesh S (2013) Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis. Pediatr Nephrol 28(2):333–338
79. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW 3rd (2011) Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 3(85):85ra46
80. Cho JH, Lee JH, Park GY, Lim JH, Kim JS, Kang YJ, Kwon O, Choi JY, Park SH, Kim YL, Kim HK, Huh S, Kim CD (2014) Successful treatment of recurrent focal segmental glomerulosclerosis with a low-dose rituximab in a kidney transplant recipient. Ren Fail 36(4):623–626
81. Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang JM, Chen HC, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke GW 3rd, Mundel P (2013) Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 369(25):2416–2423
82. Garin EH, Reiser J, Cara-Fuentes G, Wei C, Matar D, Wang H, Alachkar N, Johnson RJ (2014) Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. Pediatr Nephrol. doi:10.1007/s00467-014-2957-6
83. Belingheri M, Lazzari L, Parazzi V, Groppali E, Biagi E, Gaipa G, Giordano R, Rastaldi MP, Croci D, Biondi A, Rebulla P, Edefonti A, Ghio L (2013) Allogeneic mesenchymal stem cell infusion for the stabilization of focal segmental glomerulosclerosis. Biologicals 41(6):439–445
84. Vanikar AV, Trivedi HL, Shah PR, Kanodia KV, Patel RD, Modi PR, Dave SD, Singhai AM, Shah VR, Trivedi VB, Shankar V (2013) Single-center experience on renal transplantation in primary focal and segmental glomerulosclerosis using hematopoietic stem cell transplantation in thymus, bone marrow, portal and peripheral circulation. Saudi J Kidney Dis Transpl 24(1):15–21
85. Suthanthiran M, Schwartz JE, Ding R, Abecassis M, Dadhania D, Samstein B, Knechtle SJ, Friedewald J, Becker YT, Sharma VK, Williams NM, Chang CS, Hoang C, Muthukumar T, August P, Keslar KS, Fairchild RL, Hricik DE, Heeger PS, Han L, Liu J, Riggs M, Ikle DN, Bridges ND, Shaked A (2013) Clinical Trials in Organ Transplantation 04 (CTOT-04) Study Investigators. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med 369(1):20–31
86. Beaudreuil S, Zhang X, Kriaa F, Dantal J, Francois H, Vazquez A, Charpentier B, Lorenzo HK, Durrbach A (2014) Protein A immunoadsorption cannot significantly remove the soluble receptor of urokinase from sera of patients with recurrent focal segmental glomerulosclerosis. Nephrol Dial Transplant 29(2):458–463